NanoVibronix (NASDAQ: NAOV) is one of 28 publicly-traded companies in the “Surgical appliances & supplies” industry, but how does it weigh in compared to its rivals? We will compare NanoVibronix to related businesses based on the strength of its institutional ownership, analyst recommendations, profitability, dividends, earnings, valuation and risk.
Risk and Volatility
NanoVibronix has a beta of -0.14, indicating that its stock price is 114% less volatile than the S&P 500. Comparatively, NanoVibronix’s rivals have a beta of 1.14, indicating that their average stock price is 14% more volatile than the S&P 500.
This table compares NanoVibronix and its rivals gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|NanoVibronix Competitors||$1.35 billion||$134.43 million||17.38|
NanoVibronix’s rivals have higher revenue and earnings than NanoVibronix. NanoVibronix is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
This table compares NanoVibronix and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Institutional and Insider Ownership
14.2% of NanoVibronix shares are held by institutional investors. Comparatively, 58.3% of shares of all “Surgical appliances & supplies” companies are held by institutional investors. 18.7% of NanoVibronix shares are held by insiders. Comparatively, 9.5% of shares of all “Surgical appliances & supplies” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
This is a summary of recent ratings and price targets for NanoVibronix and its rivals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
As a group, “Surgical appliances & supplies” companies have a potential upside of 19.42%. Given NanoVibronix’s rivals higher probable upside, analysts clearly believe NanoVibronix has less favorable growth aspects than its rivals.
NanoVibronix rivals beat NanoVibronix on 9 of the 13 factors compared.
NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. Its products include UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use; PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; and WoundShield, a patch-based therapeutic ultrasound device, which facilitates tissue regeneration and wound healing. The company sells its products in the United States, Israel, Europe, India, and internationally through distributor agreements. NanoVibronix, Inc. was founded in 2003 and is based in Elmsford, New York.
Receive News & Ratings for NanoVibronix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NanoVibronix and related companies with MarketBeat.com's FREE daily email newsletter.